CN116804630B - 一种血清同型半胱氨酸测定试剂盒 - Google Patents
一种血清同型半胱氨酸测定试剂盒 Download PDFInfo
- Publication number
- CN116804630B CN116804630B CN202310971610.5A CN202310971610A CN116804630B CN 116804630 B CN116804630 B CN 116804630B CN 202310971610 A CN202310971610 A CN 202310971610A CN 116804630 B CN116804630 B CN 116804630B
- Authority
- CN
- China
- Prior art keywords
- reagent
- homocysteine
- assay kit
- mmol
- homocysteine assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 title claims abstract description 57
- 238000003149 assay kit Methods 0.000 title claims abstract description 23
- 210000002966 serum Anatomy 0.000 title claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 111
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000003755 preservative agent Substances 0.000 claims abstract description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 5
- 239000000872 buffer Substances 0.000 claims abstract description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 4
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 claims abstract description 3
- 102000016901 Glutamate dehydrogenase Human genes 0.000 claims abstract description 3
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 claims abstract 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims abstract 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims abstract 2
- 108010020869 Homocysteine S-Methyltransferase Proteins 0.000 claims abstract 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims abstract 2
- 229960001570 ademetionine Drugs 0.000 claims abstract 2
- 239000007853 buffer solution Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- -1 polyoxypropylene stearate Polymers 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 6
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 claims description 2
- 102000005234 Adenosylhomocysteinase Human genes 0.000 claims description 2
- 108020002202 Adenosylhomocysteinase Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 239000004094 surface-active agent Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 102000004157 Hydrolases Human genes 0.000 abstract description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 abstract 2
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 abstract 2
- 102000055027 Protein Methyltransferases Human genes 0.000 abstract 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 abstract 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 abstract 1
- 229940052665 nadh Drugs 0.000 abstract 1
- 229940001482 sodium sulfite Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 26
- 238000001514 detection method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 2
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 2
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010060919 Foetal malformation Diseases 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000003225 hyperhomocysteinemia Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90611—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general
- G01N2333/90616—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1) in general with a definite EC number (1.4.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Pathology (AREA)
Abstract
本发明提供一种同型半胱氨酸测定试剂盒，试剂盒含有试剂R1和试剂R2；试剂R1中含有以下成分：三羟甲基氨基甲烷‑盐酸缓冲液、三(2羧乙基)膦氯化氢、NADH、亚硫酸钠、S‑腺苷甲硫氨酸、α－酮戊二酸、表面活性剂、防腐剂；试剂R2：三羟甲基氨基甲烷‑盐酸缓冲液、同型半胱氨酸甲基转移酶、谷氨酸脱氢酶、S‑腺苷同型半胱氨酸(SAH)水解酶、腺苷脱氨酶、表面活性剂、防腐剂。本发明同时提供了该试剂盒的制备方法和应用，该试剂盒是一种稳定性强，灵敏度高，重复性好的液体试剂盒。
Description
技术领域
本发明涉及生化试剂测定技术领域，特别涉及一种同型半胱氨酸测定试剂盒，还涉及所述同型半胱氨酸测定试剂盒制备方法和应用。
背景技术
同型半胱氨酸(HCY)是人们日常饮食中的蛋白类物质在体内转化、代谢过程所产生的一种中间产物，它通过甲基化和转硫途径进行代谢，维持着人体的甲基化和抗氧化两大能力。
HCY具有重要的临床意义：1、HCY与心血管系统疾病；同型半胱氨酸自1931年被Vincent du Vigneaud发现，1969年McCully首次提出高水平的同型半胱氨酸浓度是引起血管病变的原因，从此，HCY逐渐引起研究者的注意，到目前为止，大量对HCY的研究表明HCY是心脑血管疾病的独立危险因素，危险度随着浓度的升高而增加。高浓度的HCY与未来的冠心病和导致的死亡有重要的相关性。对国人来说，HCY浓度＞9.47μmol/L，心血管患病率增加2.3倍；HCY浓度＞11.84μmol/L，死亡增加2.4倍。2、HCY与妊娠期相关疾病；孕产妇HCY水平升高影响胎儿生长发育的原因：母亲高HCY会引起胎盘血管内皮细胞损伤、血管硬化，减少胎盘血流灌注，致使供氧、营养物质不足，影响胎儿发育。影响胎儿对蛋氨酸的利用，从而影响到胎儿的生长发育。HCY水平升高是叶酸缺乏的表现，叶酸是合成DNA的重要辅酶，在胎儿生长发育中起到重要作用。血浆中HCY水平升高与习惯性流产、妊娠高血压综合征、胎盘早剥、胎儿生长受限、胎儿畸形、死胎、早产、低体重儿等的发生密切相关。孕妇妊娠期缺乏叶酸及Vit B将可能发生高同型半胱氨酸血症，从而对母儿造成危害。3、HCY与糖尿病；高HCY血症是引起糖尿病慢性并发症的又一重要危险因素(如糖尿病肾病，动脉斑块，糖尿病视网膜病变等)。4、HCY与老年痴呆；血浆HCY水平升高对于发展为痴呆和老年性痴呆是一个强大的、独立的危险因子。血浆HCY升高5μmol/L，患老年性痴呆的危险性增加40％。
临床或实验室诊断方法有比色法、色谱法、同位素法等。目前检测同型半胱氨酸的方法主要是生化试剂中的比色法，该方法具有特异性高，操作简单快捷、安全、可自动化分析、成本较低的优点。目前生化试剂有双试剂和三试剂的水解酶法和胱硫醚法，胱硫醚法准确度差，水解酶法稳定性差，成本较高。本发明针对现有水解酶法同型半胱氨酸试剂盒的缺点进行改进以满足临床检测以及化学分析的要求。
发明内容
为了解决上述问题，本发明提供一种同型半胱氨酸测定试剂盒及其制备方法和应用，该试剂盒是一种稳定性强，灵敏度高，重复性好的液体试剂盒。
本发明是通过以下技术方案实现的：
一种同型半胱氨酸测定试剂盒，试剂盒含有试剂R1和试剂R2；
试剂R1中含有以下成分：
试剂R2中含有以下成分：
优选地，所述试剂R1和R2的缓冲液选自三羟甲基氨基甲烷-盐酸缓冲液。
优选地，所述试剂R1的pH为8.5-9.5，更优选地为8.8；试剂R2的pH为7.5-8.5，更优选地为8.0。
优选地，所述试剂R2试剂中的表面活性剂选自吐温系列、司盘系列、曲拉通系列和聚氧丙烯硬脂酸酯中的一种或多种，更优选地为聚氧丙烯硬脂酸酯和司盘20。
优选地，所述试剂R1和R2试剂中的防腐剂为叠氮钠、proclin300、MIT、硫柳汞和硫酸庆大霉素中的一种或多种，更优选地为叠氮钠。
优选地，所述试剂R1与试剂R2的体积比为1～5:1。更优选地，所述试剂R1与试剂R2的体积比为4:1。
上述所述的同型半胱氨酸测定试剂盒的制备方法，包括以下步骤：试剂R1、R2均先加入三羟甲基氨基甲烷-盐酸缓冲液，用盐酸或氢氧化钠调节pH，试剂R1的pH值为8.8，R的pH值为8.0，再按照比例添加其他物质溶解，制成同型半胱氨酸测定试剂盒。
本发明还公开了同型半胱氨酸测定试剂盒的应用，用于非疾病的诊断和治疗目的测定血清中同型半胱氨酸的浓度。
本发明试剂盒采用比色法，其反应原理为基于小分子捕获技术(SMT)的S-腺苷同型半胱氨酸水解酶。同型半胱氨酸被转化为游离型后，通过与共价底物反应，循环放大，同时产生腺苷。腺苷立即水解成氨和次黄嘌呤，氨在谷氨酸脱氢酶的作用下，使NADH转化为NAD,样本中的同型半胱氨酸浓度与NADH转化速率成正比。反应具有特异性，使用全自动生化仪进行检测，操作简单、自动化程度高，可减少人为误差，试剂稳定，适合大多数临床实验室应用。
有益效果
1)本发明稳定的同型半胱氨酸测定试剂盒为液体双试剂，无需复溶配制，开瓶可以直接使用。
2)通过在试剂R1中加亚硫酸钠，有效地降低试剂中TCEP的氧化，且降低了干扰物质对TCEP的影响，大大增强试剂的分析灵敏度，提高试剂性能。
3)通过在试剂R2中加入聚氧丙烯硬脂酸酯和司盘20，两种成分共同作用，可以有效地降低多种酶的相互作用，防止多种酶的相互聚沉，提高试剂的准确性和稳定性。
4)该试剂的准确度、稳定性、分析灵敏度等性能指标卓越，价格便宜，使用方便，有利于该试剂在市场中进一步推广。
附图说明
图1为实施例1试剂和对比例1试剂的相关性曲线；
图2为实施例1试剂线性的相关性曲线；
图3为实施例1试剂和对比例1、3、4、5试剂进行稳定性试验的浓度变化。
具体实施方式
下面结合具体实施例对本发明进行进一步说明：
本实施例所述试剂盒，在使用时，其测定方法是采用具有双试剂功能的迈瑞800全自动生化分析仪，利用速率法进行测定，检测主波长为340nm，操作如下：
加入生理盐水、样本或校准品12μL，再加入240μL的R1试剂，预孵育5min后，记录吸光度值A1；
再加入60μL的R2试剂，混匀，反应5min后，记录吸光度值A2，并计算ΔA。
同型半胱氨酸含量(umol/L)＝(ΔA样本÷ΔA校准品)×校准品浓度。
样本要求：
1.不溶血血清。
2.样本稳定性：标本2～8℃保存可稳定3天，-20℃保存可稳定2周。
实施例1
一种常规的同型半胱氨酸测定试剂盒，它包括试剂R1和试剂R2。
试剂R1中含有以下成分：
试剂R2中含有以下成分：
本实施例所述试剂R1和试剂R2，配制时需先配制三羟甲基氨基甲烷-盐酸缓冲液，用盐酸或氢氧化钠调节pH，试剂R1的pH值调节为8.8，试剂R2的pH为8.0。再按照比例添加其他物质溶解，制成同型半胱氨酸测定试剂。
所述的检测试剂，试剂R1与试剂R2的比例为4:1。
对比例1
市售的进口同型半胱氨酸测定试剂盒。
对比例2
与实施例1中同型半胱氨酸测定试剂盒的区别仅在于试剂R1中不含亚硫酸钠，其它与实施例1相同。
对比例3
与实施例1中同型半胱氨酸测定试剂盒的区别仅在于试剂R2中不含聚氧丙烯硬脂酸酯，司盘-20为2ml/L，其它与实施例1相同。
对比例4
与实施例1中同型半胱氨酸测定试剂盒的区别仅在于试剂R2中不含司盘-20，聚氧丙烯硬脂酸酯为2ml/L，其它与实施例1相同。
对比例5
与实施例1中同型半胱氨酸测定试剂盒的区别仅在于试剂R2中不含聚氧丙烯硬脂酸酯和司盘-20，替换为曲拉通x-100为2ml，其它与实施例1相同。
性能验证
试验一
相关性实验：实验方案为：实施例1试剂、对比例1试剂，同时检测了20个临床血清样本，对两组检测结果进行相关性分析，计算相关系数r；以对比例1试剂检测结果作为对照值，分别计算20对数据的相对偏差(r)。要求r不小于0.99，相对偏差不超过±10％。检测结果如表1所示，并获得了实施例1试剂和对比例1试剂的相关性曲线(如图1所示)。
表1相关性对比实验结果
表2对比例1试剂分别与实施例1试剂的相关系数
由表1和图1的可以看出，实施例1试剂和对比例1试剂的试剂盒血清测试偏差最大值为4.60％，两种试剂的相关系数大于0.99，实施例1试剂和对比例1试剂的检测结果非常接近，因此本发明提供的实施例1试剂与的进口试剂相关性良好，完全可以替代进口试剂，满足临床需求。
试验二
分析灵敏度实验：把质控稀释到靶值为0.4umol/L，用实施例1、对比例1和对比例2分别检测10次检测，将共10次检测结果计算平均值、标准差和变异系数。检测结果如表3所示。
表3质控检测结果
由表3可以看出，实施例1试剂检测数值接近靶值，标准偏差小，变异系数小，重复性较好。实施例1试剂的分析灵敏度显著的优于对比例1试剂和对比例2试剂。说明亚硫酸钠能够很好的保护TCEP，降低干扰物质对TCEP的影响，从而显著的提高试剂的分析灵敏度。实施例1试剂能够较好达到检测临床病例样本的要求，对于临床检验有重要意义。
试验三
线性实验：取同型半胱氨酸高值样本为60umol/L，并进行稀释，配制7个不同浓度的样本，依次为60.0umol/L、30.0umol/L、15.0umol/L、7.5umol/L、3.75umol/L、1.975umol/L、0.0umol/L浓度的样本，每个浓度水平各样本分别测定三次，分别取其平均值。用实施例1的试剂进行检测。检测结果如表所示。
表4线性相关验证实验检测结果
| 理论浓度(umol/L) | 检测结果(umol/L) |
| 0.0 | -0.05 |
| 1.975 | 2.10 |
| 3.75 | 4.00 |
| 7.5 | 8.10 |
| 15.0 | 16.65 |
| 30.0 | 32.70 |
| 60.0 | 59.55 |
| 相关系数R | 0.999 |
由表4和图2可以看出，本发明实施例1试剂随稀释浓度呈线性变化，线性相关系数达到0.999，大于0.990，说明实施例1试剂线性范围较好，能够符合临床病例样本的要求，对于临床检验有重要意义。
试验四
热稳定性实验：对实施例1试剂和对比例1、3、4、5试剂进行稳定性试验，试验方案为：对实施例1试剂和对比例1、3、4、5试剂，一起放入37℃水浴箱中，每天检测靶值为29.0±2.9umol/L的质控品，并监测质控品测定值的变化。
表5试剂热稳定性验证结果
由表5和图3可以看出，本发明提供的实施例1试剂在37℃水浴条件下10天内基本无变化，稳定性较好；而对比例1、3、4、5试剂在37℃水浴条件下10天内较实施例1变化明显。实施例1的试剂稳定性优于对比实施例1试剂的稳定性。同时对比例3试剂和对比例4试剂说明一种表面活性剂的加入可以一定程度的提高试剂的稳定性。对比例5试剂稳定性差说明普通表面活性剂不能起到提高稳定性的作用。所以两种表面活性剂协同增效，共同提高了试剂的稳定性。
综上所述，本发明一种同型半胱氨酸检测试剂在临床样本检测时与对比例1试剂有较好的相关性，但是在稳定性和分析灵敏度等方面均优于对比例1试剂，为本发明试剂盒提供了良好的发展空间，同时增强了本发明试剂盒在市场上竞争力。
本文中所描述的具体实施例仅仅是对本发明精神作举例说明。本发明所属技术领域的技术人员可以对所描述的具体实施例做各种修改或补充或采用类似的方式替代，但并不会偏离本发明的精神或者超越所附权利要求书所定义的范围。
Claims (7)
1.一种同型半胱氨酸测定试剂盒，其特征在于，试剂盒含有试剂R1和试剂R2；
试剂R1中含有以下成分：
缓冲液 50~120 mmol/L；
三（2羧乙基）膦氯化氢 1~5 mmol/L；
NADH 0.1~1 mmol/L；
S-腺苷甲硫氨酸 0.05~1 mmol/L；
α－酮戊二酸 0.5~2 mmol/L；
亚硫酸钠 1-5g/L；
防腐剂 0.5 ~1 g/L；
试剂R2中含有以下成分：
缓冲液 50~120 mmol/L；
同型半胱氨酸甲基转移酶 0.5~4.0 KU/L；
谷氨酸脱氢酶 50~100 KU/L；
S-腺苷同型半胱氨酸水解酶 0.1~2. 0 KU/L；
腺苷脱氨酶 10-50 KU/L；
聚氧丙烯硬脂酸酯 1ml/L；
司盘-20 1ml/L；
防腐剂 0.5~1 g/L。
2.根据权利要求1所述的同型半胱氨酸测定试剂盒，其特征在于，所述试剂的缓冲液体系为三羟甲基氨基甲烷-盐酸缓冲液、4-羟乙基哌嗪乙磺酸缓冲液、哌嗪-1,4-二乙磺酸缓冲液、磷酸盐缓冲液、N-氨基甲酰甲基乙磺酸缓冲液和2-(N-吗啉代)乙磺酸缓冲液中的一种。
3.根据权利要求1所述的同型半胱氨酸测定试剂盒，其特征在于，所述试剂R1的pH为8.5-9.5，试剂R2的pH为7.5-8.5。
4.根据权利要求1所述的同型半胱氨酸测定试剂盒，其特征在于，所述试剂 R1和R2试剂中的防腐剂为叠氮钠、proclin300、MIT、硫柳汞和硫酸庆大霉素中的一种或多种。
5.根据权利要求1所述的同型半胱氨酸测定试剂盒，其特征在于，所述试剂R1与试剂R2的体积比为1～5:1。
6.一种权利要求1-5之一所述的同型半胱氨酸测定试剂盒的制备方法，其特征在于，包括以下步骤：试剂R1、R2均先加入缓冲液，用盐酸或氢氧化钠调节pH，R1的pH为8.5-9.5，R2的pH为7.5-8.5，再按照比例添加其他物质溶解，制成同型半胱氨酸测定试剂盒。
7.一种权利要求1-5之一所述的同型半胱氨酸测定试剂盒的应用，用于非疾病的诊断和治疗目的测定血清中同型半胱氨酸的浓度。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310971610.5A CN116804630B (zh) | 2023-08-03 | 2023-08-03 | 一种血清同型半胱氨酸测定试剂盒 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310971610.5A CN116804630B (zh) | 2023-08-03 | 2023-08-03 | 一种血清同型半胱氨酸测定试剂盒 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116804630A CN116804630A (zh) | 2023-09-26 |
| CN116804630B true CN116804630B (zh) | 2024-03-05 |
Family
ID=88079603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310971610.5A Active CN116804630B (zh) | 2023-08-03 | 2023-08-03 | 一种血清同型半胱氨酸测定试剂盒 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116804630B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117368492B (zh) * | 2023-12-04 | 2024-03-08 | 迪亚莱博（张家港）生物科技有限公司 | 一种同型半胱氨酸检测试剂盒 |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435877A (en) * | 1973-10-18 | 1976-05-19 | Shionogi & Co | Composition and test strip for detecting homocystinuria and cystinuria |
| US6638711B1 (en) * | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| CN104030839A (zh) * | 2014-07-01 | 2014-09-10 | 成都新柯力化工科技有限公司 | 一种纳米胶囊缓释肥及其制备方法 |
| CN105296596A (zh) * | 2015-11-17 | 2016-02-03 | 山东博科生物产业有限公司 | 一种稳定性强的酶法同型半胱氨酸检测试剂盒 |
| CN109929548A (zh) * | 2019-04-15 | 2019-06-25 | 济南大学 | 一种用于羧肽酶a检测的新型近红外荧光探针 |
| CN110308282A (zh) * | 2019-06-21 | 2019-10-08 | 中生北控生物科技股份有限公司 | 一种稳定的同型半胱氨酸循环酶法检测试剂盒 |
| CN110590726A (zh) * | 2019-09-04 | 2019-12-20 | 中南大学 | 一种同时区分Cys/Hcy和GSH的开关型荧光探针 |
| CN111304283A (zh) * | 2020-03-05 | 2020-06-19 | 安徽大千生物工程有限公司 | 一种基于循环酶速率法测定hcy的试剂盒及其制备使用方法 |
| CN111689954A (zh) * | 2020-07-23 | 2020-09-22 | 济南大学 | 一种检测次氯酸并引发光动力学治疗和铁死亡的荧光探针 |
| CN112485231A (zh) * | 2019-09-12 | 2021-03-12 | 宁波大学 | 一种二氧化硫和谷胱甘肽联合检测试剂盒 |
| CN113021814A (zh) * | 2019-12-25 | 2021-06-25 | 惠州比亚迪电子有限公司 | 一种注塑产品熔接线的检测溶液及检测方法 |
| WO2022123495A1 (en) * | 2020-12-09 | 2022-06-16 | Diana Biotechnologies, S.R.O. | Detection of nucleic acids using direct rt-pcr from biological samples |
| CN116165309A (zh) * | 2022-06-16 | 2023-05-26 | 苏州帕诺米克生物科技有限公司 | 稀释溶剂、同型半胱氨酸质控品及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112543A1 (en) * | 1998-03-11 | 2005-05-26 | The General Hospital Corporation | Method of screening for drugs useful in treating Alzheimer's disease |
| US20090274660A1 (en) * | 1999-08-17 | 2009-11-05 | Immunopath Profile, Inc. | Pluripotent therapeutic compositions and uses thereof |
| WO2007145987A1 (en) * | 2006-06-06 | 2007-12-21 | University Of Utah Research Foundation | J-superfamily conotoxin peptides |
| KR20150042291A (ko) * | 2006-10-05 | 2015-04-20 | 이카리아 인코포레이티드 | 액체 칼코게나이드 조성물 및 이의 제조방법과 사용방법 |
| WO2009062967A1 (en) * | 2007-11-12 | 2009-05-22 | Becton, Dickinson & Company | Ms-compatible nonionic or zwitterionic surfactants in free-flow electrophoresis |
| JP2012519284A (ja) * | 2009-02-27 | 2012-08-23 | ベックマン コールター， インコーポレイテッド | 選択的シグナル阻害剤を用いた非分離アッセイ |
| TWI560202B (en) * | 2011-12-22 | 2016-12-01 | Pfizer | Anti-diabetic compounds |
| WO2020068185A2 (en) * | 2018-05-30 | 2020-04-02 | Zymergen Inc. | Monothioether crosslinkers in polymers and applications thereof |
| WO2021062000A1 (en) * | 2019-09-27 | 2021-04-01 | Portland State University | Seminaphthofluorophore-selenium probes for thioredoxin reductase |
-
2023
- 2023-08-03 CN CN202310971610.5A patent/CN116804630B/zh active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1435877A (en) * | 1973-10-18 | 1976-05-19 | Shionogi & Co | Composition and test strip for detecting homocystinuria and cystinuria |
| US6638711B1 (en) * | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| CN104030839A (zh) * | 2014-07-01 | 2014-09-10 | 成都新柯力化工科技有限公司 | 一种纳米胶囊缓释肥及其制备方法 |
| CN105296596A (zh) * | 2015-11-17 | 2016-02-03 | 山东博科生物产业有限公司 | 一种稳定性强的酶法同型半胱氨酸检测试剂盒 |
| CN109929548A (zh) * | 2019-04-15 | 2019-06-25 | 济南大学 | 一种用于羧肽酶a检测的新型近红外荧光探针 |
| CN110308282A (zh) * | 2019-06-21 | 2019-10-08 | 中生北控生物科技股份有限公司 | 一种稳定的同型半胱氨酸循环酶法检测试剂盒 |
| CN110590726A (zh) * | 2019-09-04 | 2019-12-20 | 中南大学 | 一种同时区分Cys/Hcy和GSH的开关型荧光探针 |
| CN112485231A (zh) * | 2019-09-12 | 2021-03-12 | 宁波大学 | 一种二氧化硫和谷胱甘肽联合检测试剂盒 |
| CN113021814A (zh) * | 2019-12-25 | 2021-06-25 | 惠州比亚迪电子有限公司 | 一种注塑产品熔接线的检测溶液及检测方法 |
| CN111304283A (zh) * | 2020-03-05 | 2020-06-19 | 安徽大千生物工程有限公司 | 一种基于循环酶速率法测定hcy的试剂盒及其制备使用方法 |
| CN111689954A (zh) * | 2020-07-23 | 2020-09-22 | 济南大学 | 一种检测次氯酸并引发光动力学治疗和铁死亡的荧光探针 |
| WO2022123495A1 (en) * | 2020-12-09 | 2022-06-16 | Diana Biotechnologies, S.R.O. | Detection of nucleic acids using direct rt-pcr from biological samples |
| CN116165309A (zh) * | 2022-06-16 | 2023-05-26 | 苏州帕诺米克生物科技有限公司 | 稀释溶剂、同型半胱氨酸质控品及应用 |
Non-Patent Citations (3)
| Title |
|---|
| Dai Chongwen 等.High-performance liquid chromatographic assay for plasma total homocysteine.《Hunan Yikedaxue xuebao》.2002,第27卷(第6期),556-558. * |
| 宋文婷 ; 李磊 ; 林成仁 ; 刘建勋 ; .HPLC-ECD法测定大鼠血浆中同型半胱氨酸的含量.中国实验方剂学杂志.2010,(03),123-125. * |
| 王丽珍 ; 张敬各 ; 王树人 ; .同型半胱氨酸对人血管平滑肌细胞5,10-亚甲基四氢叶酸还原酶基因启动子甲基化修饰及mRNA表达的影响.卫生研究.2007,(03),36-39. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116804630A (zh) | 2023-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102435749B (zh) | 用循环酶法测定β-羟丁酸的液体稳定试剂盒 | |
| CN116804630B (zh) | 一种血清同型半胱氨酸测定试剂盒 | |
| CN101503732B (zh) | 一种葡萄糖氧化酶单一液体测定试剂 | |
| CN109212176B (zh) | 一种丙酮酸测定试剂盒及其制备方法和应用 | |
| CN104483487A (zh) | 检测人血液中1,5-脱水山梨醇的试剂盒 | |
| CN109517813B (zh) | 一种肌酸激酶及其同工酶激活剂、测定试剂及试剂盒 | |
| CN102154442A (zh) | 1,5-脱水山梨醇的检测方法和相关诊断试剂盒 | |
| Warner et al. | Prognostic role of antioxidant enzymes in sepsis: preliminary assessment | |
| CN111304283A (zh) | 一种基于循环酶速率法测定hcy的试剂盒及其制备使用方法 | |
| CN104237147A (zh) | 体液中乳糖测定方法 | |
| CN109988816A (zh) | 一种腺苷脱氨酶测定试剂盒 | |
| CN112710853B (zh) | 一种抗干扰、稳定的血清直接胆红素（酶法）测定试剂盒及其制备方法和应用 | |
| CN112255219A (zh) | 一种1,5-脱水山梨醇的测定试剂盒及其制备方法和应用 | |
| CN102564979A (zh) | 循环酶法测定乙醇浓度的方法及乙醇测定试剂盒 | |
| CN104807995B (zh) | 一种灵敏度高的连续检测法gldh检测试剂 | |
| CN107653298A (zh) | 腺苷脱氨酶测定试剂盒 | |
| CN103952461A (zh) | 一种重复性好的同型半胱氨酸检测试剂盒 | |
| CN107153044A (zh) | 一种改良型的同型半胱氨酸试剂盒及其检测方法 | |
| CN105400862B (zh) | 一种葡萄糖检测试剂盒 | |
| Gutensohn et al. | Rapid assay for purine phosphoribosyltransferases | |
| CN109097434B (zh) | 一种唾液酸检测试剂盒 | |
| WO1997039352A1 (en) | Assays for detection of purine metabolites | |
| CN110849870A (zh) | 一种N-乙酰-β-D-氨基葡萄糖苷酶的检测试剂 | |
| CN114480563A (zh) | 一种检测腺苷脱氨酶活性的组合物及试剂盒 | |
| Lamb et al. | 21 Kidney Function Tests—Creatinine, Urea, and Uric Acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |